Edit
Sapience Therapeutics, Inc.
https://www.sapiencetherapeutics.com/Last activity: 01.12.2021
Active
At Sapience, our mission is clear - to create novel medicines for those suffering from difficult to treat cancers by targeting previously undruggable proteins in cancer cells. To do this, we use our library-based platform called PADS to enable discovery of new molecular entities and generate a pipeline of novel peptide drug candidates.
Many cancer drugs on the market and in development have limitations that prevent them from addressing potentially important drug targets within the cancer cell, the so-called undruggable targets. Our data suggests that our therapeutic approach, which utilizes peptides, may bypass these limitations. Our lead drug candidate and prototype, ST101, initiated a Phase 1/2 clinical trial in July 2020, in patients with advanced unresectable and metastatic solid tumors. In our pre-clinical pipeline, which spans early discovery through late stage lead selection, we have peptides that may address well regarded cancer targets, including β-catenin, Myc, cJun, FOXP3 and more.
Many cancer drugs on the market and in development have limitations that prevent them from addressing potentially important drug targets within the cancer cell, the so-called undruggable targets. Our data suggests that our therapeutic approach, which utilizes peptides, may bypass these limitations. Our lead drug candidate and prototype, ST101, initiated a Phase 1/2 clinical trial in July 2020, in patients with advanced unresectable and metastatic solid tumors. In our pre-clinical pipeline, which spans early discovery through late stage lead selection, we have peptides that may address well regarded cancer targets, including β-catenin, Myc, cJun, FOXP3 and more.
Location: United States, New York, Harrison
Employees: 11-50
Total raised: $14M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Connectivi... | connectivi... |
| - | Eshelman V... | eshelmanve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.07.2021 | - | $14M | - |
Mentions in press and media 5
| Date | Title | Description |
| 01.12.2021 | Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference | HARRISON, N.Y., Dec. 1, 2021 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that the company will ... |
| 10.11.2021 | Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference | HARRISON, N.Y., Nov. 10, 2021 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that the company will... |
| 13.09.2021 | Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021 | |
| 15.07.2021 | Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect | HARRISON, N.Y., July 15, 2021 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today it was i... |
| 12.07.2021 | Sapience Therapeutics Completes $14 million Preferred Stock Financing | Sapience Therapeutics, Inc. , a clinical stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it has raised $14 million in its... |